Article
The ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall Short
The starting material designation in a drug substance synthesis is one of the highest-stakes decisions in small molecule CMC development — and it is made years before the…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
The ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall Short
The starting material designation in a drug substance synthesis is one of the highest-stakes decisions in small molecule CMC development — and it is made years before the…
Article
FDA Inspection Front Room Protocol — What to Say and What Not To
The most consequential decisions during an FDA inspection are not made in the laboratory or on the manufacturing floor — they are made in the first two hours…
Article
Salt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3
Salt selection is the first CMC decision that determines whether your drug will be manufacturable, stable, and bioavailable — and it is a decision made before most of…
Article
Polymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion Risk
A drug substance that exists as multiple crystalline forms — differing in lattice structure, thermodynamic stability, and solubility — is not an unusual compound. It is the majority…
Article
Risk Assessment in GMP Remediation — The ICH Q9 Practical Application
Most pharmaceutical quality risk assessments are produced in response to a regulatory request rather than to support a genuine decision — and the difference is immediately visible to…
Article
CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address
CareFusion 213, LLC, a subsidiary of Becton, Dickinson and Company (BD), has recalled two configurations of its BD ChloraPrep One-Step and FREPP Clear sterile antiseptic applicators (2% w/v…
Article
CAPA Effectiveness Verification — Closing the Loop FDA Actually Closes
An FDA investigator reviewing your CAPA system is not interested in how many CAPAs you have opened — they are interested in how many you have closed with…
Article
Chiral Drug Substances: Stereospecific Synthesis, Enantiomeric Purity, and the ICH Q6A Specification Strategy
More than half of the small molecule drugs approved by FDA in any given year contain at least one stereocenter. For most of those programs, the enantiomeric impurity…
Article
OOS Root Cause Analysis — Moving Beyond ‘Analyst Error’
"Analyst error" is not a root cause — it is a conclusion in search of evidence, and FDA’s May 2022 Level 2 revised OOS guidance is explicit that…
Article
Small Molecule CMC from Phase 1 to NDA: The Phase-Appropriate Development Strategy That Avoids Late-Stage CMC Failure
"CMC is holding up the NDA." This sentence is spoken in development teams every year — about programs where clinical and non-clinical development proceeded at the expected pace,…
Article
OOS Investigation Protocol — The CMC Framework FDA Expects
The most dangerous statement in pharmaceutical quality is "the result was retested and passed" — because that sentence, without the three-phase investigation framework that FDA requires before any…
Article
Post-Approval CMC Changes: Why ICH Q12 Is Not an Administrative Framework — It Is a Commercial Strategy
The approval of a new drug application is not the end of CMC regulatory work — it is the beginning of a decades-long change management challenge. The most…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.